Eleven names new CFO and chair of board
This article was originally published in Scrip
Executive Summary
Eleven Biotherapeutics, a clinical-stage biopharmaceutical company developing therapies for eye diseases, has appointed Gregory D Perry chief financial and business officer and Daniel S Lynch as chair of its board of directors. Eleven has also named Koltan Pharmaceuticals' senior vice-president and chief business officer Jane Pritchett Henderson as a member of its board.